UNSPSC 51141513: Carbamazepine

This classification denotes an anticonvulsant agent with the molecular formula C15H12N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 33CM23913M, chemically known as 5h-dibenz(b,f)azepine-5-carboxamide but generally known as carbamazepine, which bears US NIH Compound Identifier 2554. Carbamazepine most often comes in base, dihydrate, epoxide, and glucuronide forms. European Medicines Agency schedules Carbamazepine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06113MIG.

UNSPSC 51141513 Carbamazepine is a Commodity code that nominally covers a single antiepileptic pharmaceutical product, but the recent state and local opportunities tagged under this code reveal a broader pattern of pharmaceutical procurement spanning naloxone, generic multi-source drugs, and OTC products rather than carbamazepine specifically. State and local buyers under this code include county health departments, state health and human services agencies, and cooperative purchasing alliances representing multiple jurisdictions. The work being solicited involves establishing supply contracts for pharmaceuticals with defined specifications, NDC codes, and pricing models; managing distribution through authorized wholesalers; and ensuring compliance with FDA regulations, cGMP certification, and Drug Supply Chain Security Act requirements. Issuing bodies range from single counties to multistate cooperative purchasing vehicles, with health departments and state agencies driving procurement activity.

Geographic activity appears concentrated in Florida and Minnesota, with Texas involvement through a state-level RFI. Recent representative opportunities include Seminole County, Florida's IFB 60459723LAS (posted June 30, 2026, response due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually on a fixed-fee basis with quarterly deliveries; the Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026) exploring direct-to-manufacturer prescription capabilities outside traditional PBM and GPO channels; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) establishing multiple contracts for generic pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon. The MMCAP procurement weights price competitiveness at 75 percent, requires $5 million commercial general liability insurance and 3 percent administrative fees, and maintains authorized wholesaler chargeback relationships as mandatory. Mismatch between the code's nominal scope and actual procurement activity suggests this code captures pharmaceutical supply contracting broadly rather than carbamazepine procurement specifically.